Neuronetics : Supplemental Financial and Operating Information

Neuronetics, Inc. Supplemental Financial and Operating Information

		For the period ended December 31, 2024
		2023			2024		2023	2024
Revenue ($ thousands)	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	FY	FY
Total U.S. NeuroStar Advanced Therapy System Revenues	$3,850	$4,489	$3,597	$4,524	$3,310	$4,000	$4,108	$3,849	$16,460	$15,267
YoY Change	6%	2%	-9%	-2%	-14%	-11%	14%	-15%	-1%	-7%
Total U.S. Treatment Sessions Revenues	$10,643	$12,314	$13,060	$14,879	$12,988	$11,660	$13,326	$12,858	$50,896	$50,832
YoY Change	12%	9%	10%	20%	22%	-5%	2%	-14%	13%	0%
Total Clinic Revenues	$0	$0	$0	$0	$0	$0	$0	$4,445
YoY Change								na		na
Total U.S. Other Revenues	$471	$486	$554	$469	$495	$470	$488	$490	$1,980	$1,944
YoY Change	16%	7%	24%	5%	5%	-3%	-12%	4%	13%	-2%
Total U.S. Revenues	$14,964	$17,289	$17,211	$19,872	$16,793	$16,130	$17,922	$21,642	$69,336	$72,488
YoY Change	11%	7%	6%	13%	12%	-7%	4%	9%	9%	5%
Total International Revenues	$576	$321	$673	$442	$624	$320	$608	$851	$2,012	$2,402
YoY Change	-13%	62%	166%	-36%	8%	0%	-10%	93%	12%	19%
Total Revenues	$15,540	$17,610	$17,884	$20,313	$17,417	$16,450	$18,530	$22,493	$71,348	$74,890
YoY Change	10%	8%	8%	12%	12%	-7%	4%	11%	9%	5%
		2023			2024		2023	2024
U.S. Operating and Financial Metrics	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	FY	FY
Total NeuroStar Systems	49	54	43	58	40	50	48	47	204	185
YoY Change	7%	-8%	-14%	0%	-18%	-7%	12%	-19%	-4%	-9%